Astellas Licenses Hypotension Drug To Local Startup
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma of Japan licensed to a Keio University startup, Signal Creation, a drug it had abandoned earlier during development. Astellas inherited FK352, a drug to treat dialysis-related hypotension, when Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical merged to form Astellas in 2005. The drug got through Phase II trials before it was pulled back on concerns it would not be profitable. Astellas has several other compounds it has shelved in the past that also could be licensed. (Click here for more - a subscription may be required